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Edited by Frances ShannonAbstract A vector for preparation of mouse polyomavirus cap-
sid-like particles for transfer of foreign peptides or proteins into
cells was constructed. Model pseudocapsids carrying EGFP
fused with the C-terminal part of the VP3 minor protein
(EGFP-VLPs) have been prepared and analysed for their ability
to be internalised and processed by mouse cells and to activate
mouse and human dendritic cells (DC) in vitro. EGFP-VLPs en-
tered mouse epithelial cells, ﬁbroblasts and human and mouse
DC eﬃciently and were processed by both, lysosomes and pro-
teasomes. Surprisingly, they did not induce upregulation of DC
co-stimulation molecules or maturation markers in vitro; how-
ever, they did induce interleukin 12 secretion.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Mouse polyomavirus; Empty artiﬁcial virus-like
particle; Dendritic cell activation; Vector for peptide transfer1. Introduction
Viral coats were selected by evolution for eﬃcient entry of
viruses through the plasma membrane into cells and for deliv-
ery of genetic information into the cell nucleus or other cell
compartments for virus gene expression. Viruses thus represent
natural, highly specialised transfer vehicles.Abbreviations: AcNPV, Autographa californica nuclear polyhedrosis
virus; BMDC, bone marrow-derived dendritic cells; CFSE, carboxy-
ﬂuorescein diacetate succinimidyl ester; CM, complete culture med-
ium; DC, immature human monocyte-derived dendritic cells; EEA1,
early endosomal antigen; EGFP, enhanced green ﬂuorescent protein;
FCS, foetal calf serum; FSC and SSC, forward and side scatter char-
acteristics; EM, electron microscopy; GM-CSF, granulocyte macro-
phage-colony stimulating factor; LAMP2, lysosomal associated
membrane protein; LPS, lipopolysaccharide; NMuMG, normal mur-
ine mammary gland cells; p.a., post adsorption; p.i., post infection;
PFU, plaque forming unit; poly(I:C), inosine-cytosine dsRNA poly-
nucleotide; PyV, mouse polyomavirus; t-VP3, truncated, C-terminus of
VP3 minor capsid protein; VLPs, empty artiﬁcial virus-like particles;
VP1-VLPs, pseudocapsids composed of VP1 major capsid protein;
EGFP-VLPs, pseudocapsids composed of VP1 major capsid protein
and EGFP-t-VP3 fusion protein
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doi:10.1016/j.febslet.2005.10.062Polyomaviruses, small non-enveloped DNA viruses, have a
wide range of hosts, including human and diﬀerent pathogenic
responses in the infected organisms. Despite this variation,
these viruses share similar virion structure. The icosahedral
capsid formed by three structural proteins, VP1, VP2 and
VP3, is arranged around the nucleocore consisting of 5.3 kbp
circular genomic DNA, cellular histones (except H1) and
VP1 protein. The crystal structure of two polyomaviruses
(mouse polyomavirus (PyV) and Simian virus 40 (SV40)) has
been determined. The capsid shell is composed of 72 capso-
meres – pentamers of VP1 molecule. The major structural pro-
tein, VP1, of the PyV is formed by a sandwich core of b-sheets
with several outfacing loops [1,2], it is able to self-assemble
into capsid-like particles and is responsible for interaction with
sialic acid of ganglioside receptor [2,3]. VP1 non-speciﬁc
DNA-binding activity [4] suggests its role in the nucleocore
assembly. Neither VP2 nor VP3, which seem to interconnect
the VP1-surface lattice and the nucleohistone core [5], are re-
quired for the capsid-like structure assembly and their func-
tions are still unclear. Nevertheless, PyV with the genome
mutated in the ATG codon for either VP2 or VP3 is not infec-
tious. Also, the absence of myristyl moiety on the N-terminal
amino acid of VP2 results in a substantial decrease of polyo-
mavirus infectivity [6,7]. On the basis of the unique properties
of VP1 (ability of spontaneous self-assembly, receptor recogni-
tion, nuclear localisation signal, DNA non-speciﬁc binding
activity), studies have been performed with the aim to use
empty artiﬁcial murine polyomaviral virus-like particles (VLPs
or VP1 pseudocapsids) for gene transfer [8–10]. VLPs derived
from mouse PyV (PyV-VLPs) can cross the outer membrane of
a variety of cell types – including cells of human origin [9,11].
Studies in vivo demonstrated: (i) the ability of PyV-VLPs to
target many organs/tissues of mouse and (ii) the possibility
to introduce them into experimental animals by diﬀerent
routes, including intranasally. VLPs were shown to be able
to cross the blood–brain barrier since gene expression of the
delivered gene in the brain was observed [12]. Several studies
were performed to follow humoral and cellular immune re-
sponses to PyV VP1 pseudocapsids. They showed that such
VLPs provoked a strong cellular T helper 1 (Th1) and humoral
response and could protect mice against polyomavirus infec-
tion [13–15]. High immunogenicity of VLPs oﬀers an exploita-
tion of virus structures for development of vaccines based on
VLPs as carriers for the delivery of other disease antigens.
In this study, we have focused on development of chimeric
polyomavirus capsid structures for the transfer of epitopesblished by Elsevier B.V. All rights reserved.
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model protein to be transferred via PyV VLPs, we have chosen
the enhanced green ﬂuorescent protein (EGFP). We examined
the ability of ‘‘green’’ VLPs to enter cells and followed their
fate in the cells. Finally, we examined the eﬀects of ‘‘green’’
particles on activation of dendritic cells.2. Materials and methods
2.1. Plasmid construction
Sequences encoding the C-terminal fragment of protein VP3 (AA
105–204, nucleotides # 4345-4659) were ampliﬁed by PCR using
primers: forward: 5 0-CATCAGCGAGCTCAGGGTACTC-3 0, reverse:
5 0-TTAGAGGATCCTTAGAGACGCCGCTT-3 0, and the plasmid
pMJG (containing thewhole PyVgenomeopen in the uniqueEcoRI site;
kindly providedbyB.E.Griﬃn) as a template. ThePCR fragment aswell
as the plasmid pEGFP-C2 (Clontech, PaloAlto, CA)were cut withSacI/
BamHI and ligated to generate the plasmid pEGFP-t-VP3, where EGFP
sequences were fused in frame with truncated VP3 (t-VP3). To generate
baculovirus transfer plasmid pAcDB3/VP1/EGFP-t-VP3, sequences
encoding the fusion protein EGFP-t-VP3 were ampliﬁed by PCR using
primers: forward: 5 0-AGATAGGATCCACCATGGTGAGCAAG-3 0,
reverse: 5 0-TTAGAGGATCCTTAGAGACGCCGCTT-30, and the
pEGFP-t-VP3 as a template. The PCRproduct was cut withBglII/Bam-
HI and inserted into the plasmidpAcDB3/VP1 (with the gene for thema-
jor structural protein VP1 under the control of late p10 promoter; kind
gift of T. Ramqvist and T. Dalianis) into the BglII position under the
control of a second p10 promoter.2.2. Cell cultures and viruses
Spodoptera frugiperda (Sf9) cells were grown as monolayer cultures
at 27 C in standard TNF-FK medium containing 10% foetal calf ser-
um (FCS) as described by Hink [16]. Autographa californica nuclear
polyhedrosis virus (AcNPV) and recombinant baculoviruses were
propagated as described by OReilly et al. [17]. Recombinant baculovi-
rus AcDB3/VP1/EGFP-t-VP3 was prepared by in vivo allelic exchange
between AcNPV DNA and recombinant transfer plasmid pAcDB3/
VP1/EGFP-t-VP3, and puriﬁed by plaque assays as previously
described [17].
Normal murine mammary gland (NMuMG) epithelial cells pur-
chased from the American Type Culture Collection (no. CRL-1636)
were grown in Dulbeccos modiﬁed Eagles medium suplemented with
10% FCS (Sigma).
2.3. Human and mouse dendritic cell generation
Complete culture medium (CM) was used for the culture of
human lymphocytes and dendritic cells and consisted of RPMI
(BioWhittaker, Berkshire, England) supplemented with 10% heat-
inactivated FCS (BioWhittaker), 2 mM L-glutamine, and 1% penicil-
lin/streptomycin (BioWhittaker). Cells were cultured at 37 C in a 5%
CO2 atmosphere. Immature human monocyte-derived dendritic cells
(DC) were generated as described previously [18]. Brieﬂy, peripheral
blood mononuclear cells were obtained from buﬀy coats of healthy
donors and monocytes were separated by 2 h adhesion in 75 cm2
culture ﬂasks. Adherent monocytes were cultured for 5 days in
CM in the presence of granulocyte macrophage-colony stimulating
factor (GM-CSF) (LeukineR) and 15 ng/ml of IL-4 (Peprotech).
When indicated, immature DC were activated by the addition of
either inosine-cytosine dsRNA polynucleotide (poly(I:C)) 50 lg/ml
or lipopolysaccharide (LPS) 10 lg/ml. For generation of mouse bone
marrow dendritic cells (BMDC), bone marrow was ﬂushed from fe-
murs of C57BL/10Sn mice. Cells were plated for 5 days in 6 well
plates (5 · 105 cells/ml) in 4 ml RPMI 1640 medium supplemented
with 10% heat-inactivated FCS, 50 lM 2-mercaptoethanol, 10 mM
HEPES, penicillin (100 U/ml), streptomycin (100 lg/ml) and 5% Ag
hybridoma culture supernatant as a source of GM-CSF [19]. Every
second day the cultures were fed by aspirating 50% of medium
and adding fresh medium with GM-CSF. Mature DC were gener-
ated by incubating BMDC with GM-CSF plus 1 lg/ml LPS for
the last 18 h.2.4. Interaction of DC with polyomavirus capsid-like particles
On day 5, immature DC (human or mouse) were seeded in 24-well
plates at 5 · 105 cells/ml in CM and cultured with artiﬁcial polyomavi-
rus capsid-like particles at the DC:VLPs ratios of 1:103, 1:104, 1:105
and 1:106. Functional and phenotypic consequences of DC interaction
with VLPs were investigated after 24 h.2.5. Antibodies
Following primary antibodies were used for cell immunostaining:
anti-PyVP1 A mouse monoclonal [8] or mouse or rabbit polyclonal
antibody (prepared in our laboratory) against polyomavirus VP1;
anti-PyVP2/3A mouse monoclonal antibody against the common re-
gion of VP2 and VP3 [8]; goat anti-EEA1 (Santa Cruz) against early
endosome antigen EEA1, mixture of mouse anti-a and anti-b tubulin
(Exbio) for microtubule staining; mouse monoclonal anti-ubiquitin
antibody (Santa Cruz Biotechnology); rabbit polyclonal anti-GFP
antibody for EGFP staining (AbCam antibodies); rabbit anti-BiP
puriﬁed antiserum (Alexis) against the BiP (GRP78) marker of
endoplasmic reticulum; rat monoclonal anti-LAMP-2 antibody
(Developmental Studies Hybridoma Bank, The University of Iowa,
Iowa City) against lysosomal associated membrane protein (LAMP2).
Secondary antibodies: Alexa Fluor-546 (red) goat anti-mouse, anti-
rabbit or anti-rat antibody (Molecular Probes), Alexa Fluor-546
(red) donkey anti-goat antibody (Molecular Probes) or the Alexa
Fluor-488 (green) goat anti-mouse or anti-rabbit antibody (Molecular
Probes) were used for ﬂuorescence staining. For immunoelectron
microscopy, goat anti-mouse IgG antibody conjugated with 5 nm col-
loidal gold was used (British Biocell Int.). DNA was stained by DAPI.
For ﬂow cytometry, FITC or PE-conjugated monoclonal antibodies
(mAbs; PharMingen, San Diego, CA) against following molecules
were used: CD80, CD83, CD86, CD11c, CD40, CD11c, CD40,
HLA-ABC, HLA-DR for human dendritic cells and CD80, CD86,
CD11c and MHC class II I-Ab for mouse cells.2.6. Flow cytometry
DC were stained with antibodies for 30 min at 4 C, washed twice in
PBS + 0.1% bovine serum albumin (BSA) and analyzed in FACS Cal-
ibur (Becton Dickinson) using Cell Quest software. DC were gated
according to their FSC and SSC properties and dead cells were ex-
cluded by TO-PRO3 (Molecular Probes) staining. Appropriate isotype
controls were always included and 5 · 103 viable DC were obtained in
each experiment.2.7. FITC-dextran endocytosis
DC (2 · 105 cells) were incubated with 1 mg/ml of FITC-dextran
(40000 mw, Sigma). After 1 h, cold medium was added to stop the
experiment. Cells were washed three times with ice-cold PBS and ana-
lyzed in FACS Calibur.2.8. Cytokine detection
After the interaction with polyomavirus capsid-like particles, IL-12
p70 production by human DC and IL-12 p40 production by mouse
DC was analyzed in culture supernatants by a standard ELISA kit
(Immunotech).
2.9. Induction of lymphocyte proliferation
CD4+ T cells were positively selected using CD4 microbeads (Milt-
enyi Biotech, Bergisch Gladbach, Germany). The purity of CD4 pop-
ulation used for further studies always exceeded 95%. CD4+ T cells
were subsequently labelled by 2 lM carboxyﬂuorescein diacetate succ-
inimidyl ester (CFSE, Molecular Probes) [20]. DC (104 cells) activated
by Poly(I:C), LPS or DC that interacted with VP1 particles were cul-
tured with allogeneic CFSE-labelled CD4+ T cells (105 cells) for 4 days
and the induction of T-cell diﬀerentiation was evaluated by gradual
CFSE dilution in dividing T cells by ﬂow cytometry.2.10. Chemotaxis
DC (5 · 103 cells) in 100 ll of CM were plated in the upper chamber
of 24-well transwell plate with 5 lm porous inserts (Corning Costar).
Lower chambers contained 600 ll of medium or medium with 50 ng/
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lifted and the cells migrated to the lower surface were washed into
the lower chamber and counted.
2.11. Isolation of capsid-like particles from insect cells
Insect cells were infected with recombinant baculovirus (10 PFU/per
cell). Cells were harvested 72 h post infection (p.i.), lysed, and VLPs
were puriﬁed by CsCl and sucrose gradients as described previously [8].2.12. Immunoﬂuorescence of cells
VLPs were applied to cells grown on coverslips. At the indicated
times post adsorption (p.a.), the cells were washed with PBS, ﬁxed with
3% paraformaldehyde in PBS (15 min at 4 C) and permeabilised with
0.5% Triton X-100 (Sigma) in PBS (5 min). Fixed cells were washed
with PBS and blocked in 0.25% BSA (Sigma) and 0.25% porcine skin
gelatine (Sigma) in PBS. Incubation with primary and secondary anti-
bodies was carried out for 1.5 and 0.5 h, respectively, with extensive
washing with PBS after each of incubations. Coverslips were mounted
on droplets of glycerol with or without DAPI and samples were ob-
served in a Leica TCS SP2 confocal microscope.
2.13. Electron and immunoelectron microscopy
Mouse 3T6 or NMuMG cells grown on coverslips were infected
with pseudocapsids composed of VP1 major capsid protein and
EGFP-t-VP3 fusion protein (EGFP-VLPs) (104–105 particles/cell). At
appropriate times p.a., cells were processed for transmission electron
microscopy. Brieﬂy, the infected cells were washed in PBS, ﬁxed with
3% glutaraldehyde in 0.1 M cacodylate buﬀer, post-ﬁxed with 1%
osmium tetroxide, dehydrated through increasing ethanol series (includ-
ing 30 min contrasting in 1.5% uranylacetate in 70% ethanol) and pro-
pylenoxide, inﬁltrated, and ﬂat embedded in Agar 100 resin (Gro¨pl,
Tulln, Austria). Ultrathin sections were contrasted with a saturated
uranyl acetate solution and Reynolds lead citrate. Isolated VLPs (or
capsomeres) were immunostained against VP1 and EGFP by the direct
immunoelectron microscopy technique. VLPs were adsorbed on car-
bon-coated parlodion membrane on electron microscopy (EM) grids,
activated with glow discharge. Grids were then incubated on drops
of primary antibodies, washed intensively in PBS and exposed to col-
loidal gold-conjugated secondary antibodies. Grids were washed again
in PBS and redistilled H2O, contrasted on a drop of 2% phosphotung-
stic acid (pH 7.0) and dried. Samples were observed in a JEOL 1200EX
electron microscope operating at 60 kV.3. Results
3.1. Construction of a baculovirus for the production of mouse
polyomavirus EGFP-VLPs and their characterisation
The construction has been designed to introduce EGFP as a
fusion protein with the sequence of PyV minor capsid proteins
responsible for their interaction with the central cavity of poly-
omavirus VP1 pentameric capsomeres (Fig. 1(a)). EGFP fusedFig. 1. Design, production and detection of EGFP-VLPs. Schematic view o
producing the EGFP-t-VP3 and VP1, selectable on the basis of its green ﬂuor
Sf9 cells (confocal section of a live cell) infected with recombinant baculovirwith the C-terminal VP3 sequence was cloned into the BglII
site (under the baculovirus late promoter p10) in baculoviral
transfer plasmid pAcDB3 carrying the VP1 gene (in the SmaI
site, under the second p10 promoter). Isolated recombinant
baculovirus obtained by recombination in Sf9 insect cells gave
green plaques (Fig. 1(b)) and cell lysates were positive for both,
VP1 and fusion protein composed of EGFP and t-VP3 (not
shown). Confocal microscopy showed nuclear localisation of
the EGFP-t-VP3 product (Fig. 1(c)). We have observed previ-
ously that neither VP2 nor VP3 protein have nuclear localisa-
tion in insect cells when expressed separately. VP3 remained
spread in the cytoplasm and its nuclear localisation appeared
only in cells co-expressing the VP1 gene. This suggests that
VP3 and apparently also EGFP-t-VP3 were transported into
the cell nucleus as a complex with the major structural protein,
VP1 [3].
When lysate of cells containing VP1 and EGFP-t-VP3 pro-
teins was analysed by CsCl or sucrose gradient ultracentrifuga-
tion, we observed the green coloured band to co-purify with
the VP1 band as proved by gradient fractionation and immu-
no-dotblot (not shown). EM analysis (Fig. 2) proved that this
fraction contains high concentration of capsid-like particles.
Particles isolated from cell lysates containing VP1 only are pre-
sented for comparison (Fig. 2, third panel).
In agreement with our assumption that EGFP-t-VP3 should
be situated inside the capsid-like particle, antibody against
GFP (5 nm gold) was observed mainly in connection with sin-
gle capsomeres, or with partially disassembled but, not with in-
tact VLPs (Fig. 2, left panel), while antibody against VP1
decorated particles with a high eﬃciency (Fig. 2, middle panel).
Often imperfectly assembled ‘‘green’’ VLPs were of irregular
shape in comparison to pseudocapsids formed by VP1 only.
Nevertheless, green particles were stable during gradient cen-
trifugations, dialysis and during (at least) 1 month storage at
4 C.
3.2. EGFP-VLPs enter mammalian cells eﬃciently
Green particles were adsorbed eﬃciently on the surface of
mouse NMuMG epithelial cells and became internalised by
tightly ﬁtted smooth invaginations (Fig. 3). Thirty minutes
p.a., fusions of vesicles carrying particles into endosomes con-
taining more then one particle could be observed by EM
(Fig. 4A). However, these membrane structures could also rep-
resent one multivesicular body of inter-connected membrane
cisternae. At the same time (30 min p.a.), confocal ﬂuorescence
microscopy showed co-localisation of particles with the earlyf constructed EGFP-VLP (a). Plaque of the recombinant baculovirus
escence (b). The fusion protein EGFP localised in the nucleus of insect
us Ac-VP1-EGFP-t-VP3 60 h p.i. (c).
Fig. 2. Direct immunoelectron microscopy of EGFP-VLPs. Isolated ‘‘green’’ VLPs adsorbed on EM grids and immunostained by rabbit anti-GFP
and rabbit anti-VP1 polyclonal serum, respectively, followed by goat anti-rabbit immunoglobulin antibody conjugated with 5 nm gold particles.
VP1-VLPs were used as EGFP negative control. Lower panel represents detailed enlargements.
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signal of particles merged partially with BiP-marker of endo-
plasmic reticulum (ER) (Fig. 5). To enhance green EGFP sig-
nal of VLPs, VP1 protein of VLPs was immunostained using
Alexa Fluor-488 (green) secondary antibody (with the excep-
tion of Fig. 7).
3.3. VLPs are degraded by both lysosomes and proteasomes
Before the signal of EGFP pseudocapsids began to cumulate
in perinuclear space (90 min p.a.), co-localisation of VLPs and
LAMP2 marker of lysosomes (Fig. 6(b) and (c)) was observed,Fig. 3. EGFP-VLPs are eﬃciently internalised by NMuMG cells. After bin
membrane invaginations. Electron microscopy of ultrathin sections. Adsorpti
20 min p.a.suggesting that a subpopulation of VLPs became degraded in
lysosomal compartments. EM of ultrathin cell sections also
conﬁrmed fusion of vesicles carrying VLPs with lysosomes
(Fig. 6(a)).
Later, 6 h p.a., the majority of the VP1 and EGFP-t-VP3
was cumulated in perinuclear space, partly still in the co-local-
ising pattern (Fig. 7, upper panel). At the same time, ﬂuores-
cent signals of VP1 (red) and EGFP-t-VP3 (green) began to
translocate from perinuclear space into the cell periphery and
were separated from each other suggesting previous dissasem-
bly of ‘‘green’’ VLPs (Fig. 7, lower panel). At that time, no in-ding to the cell surface, EGFP-VLPs enter the cytoplasm in smooth
on performed with multiplicity of 104 particles per cell; Cells were ﬁxed
Fig. 4. Monopinocytic vesicles carrying EGFP-VLPs fuse with early
endosomes. (A) Electron microscopy of 3T6 (a) and NMuMG (b) cells
30 min p.a. Adsorption performed with multiplicity of 104 particles per
cell. Enlarged details of ultrathin sections (on the right). (B) Co-
localisation of VLPs (green) with EEA1 marker of early endosomes
(red). Merged image of a confocal section of the NMuMG cell ﬁxed
30 min p.a. Adsorption performed with multiplicity of 102 particles per
cell (a) with enlarged details (b).
Fig. 5. Co-localisation of EGFP-VLPs with the Bip marker of ER.
NMuMG cells ﬁxed 3 h p.a. Adsorption performed with multiplicity of
102 particles per cell. (EGFP-t-VP3 + VP1 - green, Bip - red). Sections
of diﬀerent cells, merged images.
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(not shown). Massive co-localisation of ubiquitin and EGFP-
VLP signal was observed at 8 h p.a., when the majority of
VLP signal appeared back in the cytoplasm (Fig. 8).3.4. EGFP particles enter mouse and human dendritic cells
The important point in exploitation of artiﬁcial mouse VLPs
carrying speciﬁc epitopes as vaccines is whether these particles
are able to adsorb on, enter and activate professional antigen
presenting cells (APCs). Therefore, we followed (in vitro) entry
and traﬃcking of green VLPs into human and mouse dendritic
cells and examined markers of their activation. Confocal and
EM revealed that VLPs enter both mouse and human DC eﬃ-
ciently. The endocytic pathway of VLPs in DC resembled that
observed in NMuMG cells. The VLP signal (EGFP signal en-
hanced by ‘‘green’’ immunostaining of VP1) moved via early
endosomes into perinuclear space and later (from 6 h p.a.),
the VLP signal moved back into the cytoplasm. Finally, 24 h
p.a., it could be observed near to and on the surface of den-
dritic cells (Fig. 9). At that time, substantial co-localisation
of VLP signal with ubiquitin was observed (not shown).
3.5. Mouse polyomavirus VLPs induce production of IL-12 by
DC but do not activate other DC markers in vitro
Untreated human DC produced already relatively high lev-
els of CD80 and especially CD11c, but low levels of CD83
and 86. When inoculated with pseudocapsids composed of
VP1 major capsid protein (VP1-VLP) or VP1/EGFP-t-VP3
VLPs for 24 h, no substantial upregulation of CD80, CD83,
CD86 and HLA-DR markers was observed (Fig. 10). Also,
analysis of functional characteristics: (i) phagocytic capacity,
(ii) migratory capacity of DC in response to MIP-3b and (iii)
T-cell allostimulatory capacity of DC did not demonstrate
convincing activation of human DC by polyomavirus VLPs
(Fig. 11a, b and c). On the other hand, secretion of interleukin
12 (p70 IL-12 heterodimer) was induced by incubation of hu-
man DC with EGFP-VLPs (Fig. 11d).
Similar to human DC, no substantial upregulation of CD80,
CD86 or MHCII molecules was observed in mouse DC 24 h
p.a. of VLPs composed of the VP1 only or VLPs carrying
EGFP-t-VP3 fusion proteins (not shown). The induction of
(p40) IL-12 secretion in mouse DC was achieved by high con-
centrations of VP1-VLPs or EGFP-VLPs (106–107 per cell;
Fig. 11e). Nevertheless, the same protein concentrations of bo-
vine serum albumin added to DC did not induce IL-12 produc-
tion (not shown). There was a diﬀerent correlation between
production of human and mouse DC and a total dose of VLPs
used for activation of cells. Production of IL-12 by human cells
increased with higher VLPs concentration up to l04 VLPs/cell
but, decreased when higher dose was used (105 VLPs/cell). On
the other hand, IL-12 production by mouse DC increased with
higher doses of VLPs up to 107 VLPs/cell. This observation
can be a result of diﬀerent sensitivity of human and mouse
DC to the presence of PyV VLPs. However, in contrast to ﬂow
cytometry, in these experiments, no correction for numbers of
dead cells was performed.4. Discussion
Virus-like particles of many viruses were found to be potent
inducers of immune responses against viral capsid proteins
without the need for adjuvans [21–23]. Immunisation with
papillomavirus L1 VLPs can induce high titres of neutralising
antibodies that confer protection against experimental papillo-
mavirus challenge in animal papillomavirus models [24–26].
Fig. 6. Subpopulation of EGFP-VLPs is degraded in lysosomes. Electron microscopy of ultrathin section (a): white arrows show fusion of VLP-
containing vesicles with the lysosome. Co-localisation of LAMP2 (red) and EGFP-t-VP3 +VP1 (green) on confocal sections of two diﬀerent cells,
merged images (b,c). NMuMG cells ﬁxed 90 min p.a. Adsorption performed with multiplicity of 103 particles per cell.
Fig. 7. Co-localisation of EGFP-t-VP3 (green) and VP1 (red) in NMuMG cell 6 h p.a. The majority of the VLPs in the perinuclear space and their
EGFP-t-VP3 and VP1 signals in partial co-localisation (upper panel). Separation of VP1 and EGFP-t-VP3 signals in the cytoplasm of the same cell,
shown in diﬀerent confocal section (lower panel).
Fig. 8. Co-localisation of EGFP signal with ubiquitin. EGFP-t-
VP3 + VP1 – green (a), ubiquitin – red (b), merged images of cell
section (c) and Nomarski contrast (d). Cells were ﬁxed 8 h p.a.
(multiplicity 103 VLPs per cell).
Fig. 9. EGFP-VLPs in human and mouse dendritic cells. Mouse (a,b)
and human (c,d) dendritic cells 3 h (a,c) and 24 h (b,d) p.a. of EGFP-
VLPs (multiplicity 103 VLPs/cell). Confocal sections of diﬀerent cells,
merged images; EGFP-t-VP3 + VP1 green, tubulin red and nucleus
(DAPI) blue.
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nation with L1 VLPs induced high serum antibody titres and
can protect against persistent HPV 16 infection [27]. The VLPs
can also be engineered to carry exogenous epitopes for induc-
tion of speciﬁc immune responses [28,29]. Chimeric VLPs
based on murine polyomaviruses can be prepared by inserting
Fig. 10. Activation of human dendritic cells: Flow cytometry of immature DC (iDC) and of DC activated by the treatment with LPS, poly(I:C), VP1-
VLPs and EGFP-VLPs. DC were gated according to their morphological properties and only viable cells (propidium iodide negative) were included
in the ﬁnal analysis. The thick lines represent the speciﬁc expression of investigated molecules, whereas the thin line represents the isotype control
staining. The representative proﬁles of three independent experiments with DC generated from diﬀerent donors are shown.
E. Bourˇa et al. / FEBS Letters 579 (2005) 6549–6558 6555exogenous sequences into one of the surface loops of VP1
structural protein [30,31]. However, this approach has to over-
come the restriction given by the requirement of VLP assem-
bly. VLPs with insertion in the HI loop are unstable (our
unpublished observation) and, moreover, they cannot be eﬃ-
ciently internalised by cells as they loose the ability to bind sia-
lic acid moiety of a receptor molecule. Therefore, we exploited
the C-terminal part of minor structural proteins, responsible
for their interaction with VP1 pentamers, for the introduction
of foreign peptides into VLPs. We examined the feasibility of
introduction of an exogenous protein (EGFP) into capsid pro-
tein coding sequences as a fusion tag with a truncated peptide
(99 amino acids) of the common C-terminus of VP2/VP3 min-
or structural proteins. The engineered construct was used to
study the possibility of artiﬁcial capsid formation in the nuclei
of insect cells infected by recombinant baculovirus carrying
both VP1 and EGFP-truncated VP3 (each under a strong late
baculovirus promoter).Inserted protein should be exposed inside the particle, non-
covalently connected with the central cavity of VP1 capso-
meres. Theoretically, 72 fusion proteins could be present in
one virus-like particle. Recently, such particles were assembled
in vitro from VP1 pentamers and fusion protein GFP-46 C-ter-
minal amino acids of VP2, both isolated from Escherichia coli
[32]. They achieved an average loading capacity of 64 GFP
molecules per particle. We showed that such particles can be
eﬃciently assembled in nuclei of insect cells. The yield of VLPs
accumulating in the nuclei of baculovirus-infected insect cells
was particularly high and they could be easily puriﬁed by gra-
dient centrifugations.
To further exploit chimeric VLPs carrying the desired epi-
topes connected with t-VP3 instead of EGFP, we examined
the potential of EGFP-VLPs to induce maturation of DC
in vitro. Previously, VLPs derived from the mouse polyomavi-
rus major structural protein, VP1, were analysed for the stabil-
ity and immunogenicity following intranasal administration
Fig. 11. Functional characteristics of DC after the interaction with EGFP-VPLs. FITC-dextran uptake (a) DC were pulsed with FITC-dextran
(1 mg/ml) and analyzed by FACS. Values represent relative endocytic activity of DC compared to the immature DC. Representative result of three
independent experiments with diﬀerent DC preparations is shown. Migratory capacity of DC in response to MIP-3b: (b) white bars represent the
number of DC seeded in the upper wells. Black bars show the number of cells that migrated into the lower wells of the transwell chamber. T-cell
allostimulatory capacity of DC: (c) DC that interacted with EGFP-VLPs were used as stimulators of CFSE-labelled CD4 T lymphocytes. Activation
capacity is expressed as a percentage of proliferating T cells on day 5. Secretion of IL-12 by DC interacting with EGFP-VLPs: (d,e) the quantity of
biologically active p70 IL-12 heterodimer was analyzed in supernatants from cultures of human DC 24 h p.a. of EGFP-VLPs (d) and p40 IL-12
production by mouse DC was analysed from culture supernatants 24 h p.a. of VP1-VLPs or EGFP-VLPs (e). Experiments were done three times for
each experiment with DC cultured for 5 days before addition of particles. Results of one representative experiment are shown.
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lular Th1 responses were observed after the ﬁrst dose of
VLPs and were eﬃciently boosted after a second dose [15].
Mechanism of immune system induction by PyV-VLPs re-
mains unclear. Dendritic cells are recognised as the most po-
tent professional APCs, which interact with naive T cells
and thus initiate primary immune responses. Exogenous
antigens need to be internalised and processed in the
endo-lysosomal compartments of APCs to be presented to
T cells in complex with MHC II molecules. Recently,
increasing evidence appeared that in DC, internalised exoge-
nous antigens, including VLPs, can also access the MHC
class I presentation pathway (cross-presentation). After
being captured by endocytosis, some exogenous non-cyto-
solic antigens (immune complexes, heat shock proteins,
apoptotic cells and also VLPs) can gain access to the
MHC class I pathway of antigen presenting cells by cross-
presentation through several alternative processing pathways
[33,34]. Two main routes of cross-presentation have been
proposed: one of them involves the escape of antigens from
endosomes to the cytosol following further the cytosolic
pathway used by endogenous antigens [23,35] and in the sec-
ond one, antigens are fully processed inside the endosomes
binding to recycling MHC class I molecules [36,37]. It was
shown that VLPs of hepatitis C virus [38], SHIV VLPs
[39] and also porcine parvovirus VLPs [23] entered DC eﬃ-
ciently and the uptake was followed by DC activation,
which indicates that the uptake led to antigen processing.
Also non-enveloped human or bovine papillomaviruses were
reported to induce maturation of dendritic cells in vitro byupregulating MHC class I and II molecules, CD80, CD86,
CD40, CD54, and to induce production of IL-12 p70 [40].
In the same study, human polyomaviruses BK and JC failed
to induce maturation of DC cells in vitro [40]. We showed
that neither mouse polyomavirus chimeric EGFP-VLPs nor
VLPs derived solely from the VP1 structural protein did
upregulate CD80, CD83, CD86 of human or mouse DC.
Also, in in vitro experiments, PyV-derived VLPs did not
change (i) the migratory capacity of human DC in response
to MIP-3b, (ii) the competence to stimulate T-cell prolifera-
tion and (iii) the ability of phagocytosis. Notwithstanding,
EGFP-VLPs had adsorbed on human and mouse DC and
were internalised eﬃciently. We did not observe diﬀerences
in VLP traﬃcking in ﬁbroblasts and epithelial and dendritic
cells. The endocytic pathway used by mouse polyomavirus
and VLPs is not completely understood. In the cell types
used, PyV-VLPs were internalised via a sialysed receptor
into smooth monopinocytic vesicles, which fused particularly
with early endosomes and later appeared further in recycling
endosomes and in ER cisternae compartments. Substantial
fraction of monopinocytic vesicles was also positive for cave-
olin-1 immunostaining [41]. Nevertheless, the question how
VLPs or other antigens enter the cross-presentation pathway
is currently not fully elucidated.
In contrast, as mentioned above, in vivo experiments
proved the ability of mouse polyomavirus VLPs to induce
strong humoral and cellular responses in experimental ani-
mals [13–15]. Diﬀerences in behaviour between in vitro and
in vivo treated cells may exist. One possible explanation for
induction of cellular immunity in vivo can be concealed in
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sentation by gap-junction-mediated immunological coupling
[42]. Neijssen et al. [42] showed that peptides generated by
proteosomal degradation in one cell could diﬀuse from the
cytoplasm through gap junctions to the neighbour cells.
The authors also showed that monocytes can use coupling
through gap junctions to load its own MHCI molecules with
viral peptides derived from adjacent infected cell. We ob-
served that a subpopulation of mouse PyV-VLPs appeared
in lysosomes after internalisation by DC and other cell types.
Later, the majority of VLPs entered endoplasmic reticulum
and were dispatched to the cytoplasm for degradation in pro-
teasomes. However, the signal of VP1 protein moving in the
direction to the cell periphery could be still seen 24 h p.i.
(Fig. 9). Further experiments are required to test whether
gap-junction-mediated immunological coupling plays a role
in the induction of strong immune responses to PyV-VLPs
in experimental animals. Interestingly, production of IL-12,
one of the major DC derived factors regulating T and B cell
activation was induced by mouse PyV VLPs in human and
also in mouse DC. IL-12 is a heterodimeric pro-inﬂammatory
cytokine that induces the production of interferon-c, favours
the diﬀerentiation of Th1 cells and forms a link between in-
nate resistance and adaptive immunity. IL-12 might feed back
to regulate APC in in vivo conditions. Both macrophages and
DC express functional IL-12 receptors [43].
In conclusion, we constructed VLPs derived from mouse
polyomavirus that contain foreign protein (EGFP) fused to
C-terminal sequences of minor antigens, responsible for their
interaction with the central cavity of VP1 capsomeres. These
chimeric VLPs were assembled in the nuclei of insect cells in-
fected by recombinant baculovirus and eﬃciently puriﬁed by
gradient centrifugations. Pseudocapsids were irregular in size
and often imperfectly assembled, apparently due to steric stress
caused by the presence of fusion proteins. Despite their dis-
turbed shape, they delivered foreign protein into host cells
and were eﬃciently internalised and processed also by human
and mouse dendritic cells. Neither VLPs composed of VP1
only, nor EGFP-VLPs upregulated co-stimulation molecules
and other markers of DC maturation in vitro. On the other
hand, they did induced production of the IL-12. Despite exten-
sive research, more detailed studies, both in vitro and in vivo,
will be necessary for reasonable designing of protective
vaccines.
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